Business
Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2025
Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the fourth quarter and fiscal year 2025.
About this update from Illumina, Inc.
[{"type":"text","content":"Fourth quarter 2025 results:","length":28,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of $1.16 billion, up 5% from Q4 2024 (up 4% on a constant currency basis)","length":81,"tagName":"p"}]},{"val":[{"type":"text","content":"Ex-China revenue of $1.10 billion, up 8% from Q4 2024 (up 7% on a constant currency basis)","length":90,"tagName":"p"}]},{"val":[{"type":"text","content":"GAAP operating margin of 17.4% and non-GAAP operating margin of 23.7%","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"GAAP diluted EPS of $2.16 and non-GAAP diluted EPS of $1.35","length":59,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":299,"olType":false},{"type":"text","content":"Fiscal year 2025 results:","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of $4.34 billion, flat compared to 2024 on both a reported and constant currency basis","length":94,"tagName":"p"}]},{"val":[{"type":"text","content":"Ex-China revenue of $4.10 billion, up 2% from 2024 on both a reported and constant currency basis","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"GAAP operating margin of 18.6% and non-GAAP operating margin of 23.1%","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"GAAP diluted EPS of $5.45 and non-GAAP diluted EPS of $4.84","length":59,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":319,"olType":false},{"type":"text","content":"Fiscal year 2026 guidance:","length":26,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"For fiscal year 2026, we expect:","length":32,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total company revenue of $4.5 billion to $4.6 billion, representing growth of 4% - 6% on a reported basis, including a 1.5% - 2.0% benefit from the recently closed SomaLogic acquisition","length":185,"tagName":"p"}]},{"val":[{"type":"text","content":"Ex-China Organic revenue growth of 2% - 4%, which excludes currency and acquisition impacts","length":91,"tagName":"p"}]},{"val":[{"type":"text","content":"Non-GAAP operating margin in the range of 23.3% - 23.5%, including a negative impact of 100bps from the SomaLogic acquisition","length":125,"tagName":"p"}]},{"val":[{"type":"text","content":"Non-GAAP diluted EPS in the range of $5.05 - $5.20, including...